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Wound healing is a complex process driven largely by the migration of a variety of distinct cell types from the
wound margin into the wound zone. In this study, we identify the previously uncharacterized microtubule-
severing enzyme, Fidgetin-like 2 (FL2), as a fundamental regulator of cell migration that can be targeted in vivo
using nanoparticle-encapsulated small interfering RNA (siRNA) to promote wound closure and regeneration.
In vitro, depletion of FL2 from mammalian tissue culture cells results in a more than twofold increase in the rate
of cell movement, in part due to a signiﬁcant increase in directional motility. Immunoﬂuorescence analyses
indicate that FL2 normally localizes to the cell edge, importantly to the leading edge of polarized cells, where it
regulates the organization and dynamics of the microtubule cytoskeleton. To clinically translate these ﬁndings,
we utilized a nanoparticle-based siRNA delivery platform to locally deplete FL2 in both murine full-thickness
excisional and burn wounds. Topical application of FL2 siRNA nanoparticles to either wound type results in a
signiﬁcant enhancement in the rate and quality of wound closure both clinically and histologically relative to
controls. Taken together, these results identify FL2 as a promising therapeutic target to promote the regeneration
and repair of cutaneous wounds.
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INTRODUCTION
Although wound healing is orchestrated largely by the
migration of diverse cell types from the wound edge into
the wound zone, the intracellular mechanisms that drive cell
migration have not yet been effectively harnessed for
therapeutic purposes. A potentially ideal target in this regard
is the microtubule (MT) cytoskeleton. MTs are highly
dynamic, polar polymers of tubulin with a fast growing
plus-end and a slower growing minus-end. Within cells, MTs
are organized into extremely plastic higher order arrays with
their plus-ends generally facing the cell periphery and minus-
ends oriented toward the nucleus. Although MTs are not
required for cell migration per se, there is growing evidence
that they control and coordinate multiple parameters of cell
movement including actin-based membrane protrusions
(Wehrle-Haller and Imhof, 2003; Gardel et al., 2011), the
assembly and organization of integrin-based focal adhesion
complexes (FAs) (Kaverina et al., 1998; Stehbens and
Wittmann, 2012), and the distribution and delivery of Golgi-
derived and endosomal vesicles to the leading edge
(Watanabe et al., 2005; Kaverina and Straube, 2011).
We recently showed that the migration of Drosophila
melanogaster cells was strongly enhanced by the RNA
interference–mediated depletion of the MT regulatory protein
Katanin (Zhang et al., 2011). Katanin is a conserved member
of the ATPases associated with diverse cellular activities
(AAA) protein superfamily (Roll-Mecak and McNally 2010;
Sharp and Ross 2012), which displays the capacity to sever
and depolymerize MT plus-ends in vitro (McNally and Vale,
1993). In Drosophila, Katanin localizes to the cell cortex and
normally suppresses cell movement by locally destroying
MTs (Zhang et al., 2011). Although Katanin does not regulate
the migration of most mammalian cells, our ﬁndings raised
the intriguing possibility that a related but as of yet
undetermined MT-severing enzyme could be similarly
targeted to promote cell migration and wound healing in
mammals.
We show here that a related but presently uncharacterized
protein, Fidgetin-like 2 (FL2), can be targeted to strongly
enhance the wound healing behavior of mammalian cells,
and in particular skin cells, both in vitro and in vivo. We
previously reported that Fidgetins function as MT severing and
depolymerizing enzymes (Zhang et al., 2007; Mukherjee
et al., 2012). Small interfering RNA (siRNA)-mediated
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depletion of FL2 induces a more than twofold increase in the
rates of in vitro cell movement and in vivo wound closure.
When functioning normally, FL2 localizes to regions of the
cell cortex, suppresses MT growth, and regulates the size and
distribution of FA complexes, likely through its impact on MT
dynamics. Finally, we present an innovative nanoparticle-
based topical siRNA delivery system that has allowed us to
efﬁciently reduce the expression of FL2 in murine wounds
and accelerate wound healing.
RESULTS
FL2 is a regulator of cell migration in vitro
Our interest in FL2 as a potential therapeutic target for wound
healing initiated from a siRNA-based screen for MT severing
or depolymerizing enzymes that regulate human cell motility.
This screen targeted all of the known or putative MT severing
or depolymerizing enzymes encoded by the human genome,
and the effect of siRNA treatment on the migration of
cultured U2OS cells (human osteosarcoma cells) was
measured using a standard in vitro scratch assay. Of all
targets analyzed in this screen, depletion of the previously
uncharacterized protein, FL2, had the most pronounced
effect on cellular behavior. A decrease in FL2 mRNA and
protein levels following siRNA treatment was conﬁrmed
using quantitative PCR and western blotting, respectively.
(Supplementary Figure S1A and S1C online). In particular,
FL2 siRNA treatment induced a statistically signiﬁcant ~ 2.5-
fold increase in the rate of scratch closure (Figure 1a and b;
Supplementary Movie S1 online) largely due to enhanced
cell migration into the cell-free scratch zone. Quantiﬁcation
of the movement trajectories of isolated individual cells
indicated that Fl2 siRNA treatment caused cells to move
signiﬁcantly faster and more directionally compared with
controls (Figure 1c and d). The increased rate of cell
migration caused by FL2 knockdown was rescued to control
levels when FL2 siRNA–treated cells were induced to express
an exogenous green ﬂuorescent protein (GFP)–FL2 construct
(which lacks the 3′ UTR sequences targeted by our siRNA),
ruling out off-target effects (Supplementary Figure S2A
online). Finally, a qualitatively similar enhancement of
cell migration after FL2 siRNA treatment was observed in a
human keratinocyte cell line (HaCaT) and a mouse ﬁbroblast
cell line (L929; Figure 1d; Supplementary Figure S3 online).
Thus, FL2 normally functions to suppress cell motility in a
variety of cell types relevant to mammalian cutaneous wound
healing.
It should be noted that a small but statistically signiﬁcant
increase in the proliferation rates of FL2-depleted U2OS and
L929 cells (but not HaCaTs) was also observed in our studies
(Supplementary Figure S4 online). However, we do not
believe that this can account for the enhancements of cell
migration described above as migration measurements
(Figure 1d; Supplementary Figure S2A and S3A online) were
performed on isolated cells that did not undergo mitosis
during the analysis time-course and were not pushed forward
by a proliferating cell mass (e.g., at the scratch edge). The
potential mechanisms by which FL2 inﬂuences the prolifera-
tion of some cell types will be explored in a separate study.
FL2 localizes to and regulates the organization of MTs at the cell
cortex
As a ﬁrst step toward understanding the mechanistic basis of
FL2’s impact on cell motility, we examined its subcellular
distribution using indirect immunoﬂuorescence. Multiple
monoclonal antibodies raised against different regions of FL2
showed a strong enrichment at the cortex of U2OS cells with
similar staining patterns observed in HaCaTs and L929s. This
cortical labeling was generally discontinuous and most
pronounced at the leading edge/lamellipodium of polarized
cells where it often became particularly concentrated at sites
where individual microtubule ends contacted the cortex
(Figure 1e). siRNA treatment signiﬁcantly reduced the intensity
of cortical FL2 immunostaining, supporting the speciﬁcity of
this localization pattern (Supplementary Figure S5 online).
Moreover, exogenously expressed GFP–FL2 acquired a similar
cortical localization (Supplementary Figure S6 online). By
western blot, our antibodies primarily labeled a tight doublet
running between 65 and 75 kD (Supplementary Figure S1B
online). The predicted molecular mass of FL2 is 66 kD. This
doublet was substantially reduced after FL2 siRNA treatment
strongly supporting the hypothesis it corresponds to native FL2
and that FL2 protein levels are reduced by siRNA treatment
(Supplementary Figure S1C online).
We next tested the hypothesis that FL2 impacts cell motility
via the MT cytoskeleton. Quantitative immunoﬂuorescence
performed in U2OS cells, which are particularly suited for this
kind of microscopy, owing to their size and extremely ﬂat
morphology, revealed that the depletion of FL2 signiﬁcantly
increased cellular MT polymer levels ~ 40% relative to
controls (Po0.005)—an expected outcome if FL2 normally
functions by destabilizing MTs. This siRNA phenotype was
rescued by exogenously expressed GFP–FL2 (Supplementary
Figure S2B online). Depletion of FL2 also induced the
formation of dense MT bundles just beneath the cell edge
consistent with the protein’s cortical localization (Figure 2a
and b). In addition, cells with reduced FL2 displayed a
decrease in acetylated MTs (Figure 2c and d). Acetylation is a
posttranslational modiﬁcation that usually marks a slow-
growing stable MT subpopulation (Hammond et al., 2008),
thus suggesting that FL2 normally acts on dynamic, non-
acetylated MTs. This is in contrast to Katanin that preferen-
tially severs acetylated MTs (Sudo and Baas, 2010).
In a parallel line of study, we examined how the loss of FL2
affects MT dynamics and organization by immunostaining for
EB1, a protein that speciﬁcally labels growing MT-plus ends.
MT-associated EB1 staining normally acquires a comet-like
appearance because the protein associates with tubulin
subunits as they are incorporated into the MT end and
then dissociates shortly thereafter (Vaughan, 2005).
Immunoﬂuorescence analysis showed a signiﬁcant increase
in the average number of EB1 comets at the cell edge
following FL2 knockdown, further supporting the hypothesis
that FL2 locally targets dynamic MTs (Figure 3a and b).
Moreover, the mean length of EB1 comets was signiﬁcantly
increased after FL2 knockdown, suggesting an increase in the
MT growth rate (Figure 3b). Tracking of GFP–EB1 comet
movement in living cells is standardly used to directly assess
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alterations in MT dynamics. Unfortunately, this approach was
insufﬁcient to track the elongated GFP–EB1 comets induced
by FL2 siRNA. Regardless, our data clearly demonstrate that
FL2 is an important regulator of the MT cytoskeleton in
migratory cells. A similar increase in EB1 comet number and
length, as well as a decrease in the density of acetylated MTs,
was also observed in HaCaTs (Figure 3b; Supplementary
Figure S7A online).
FL2 impacts FA size and maturity
Integrin-based FAs are integral factors in the migration of large
cells such as ﬁbroblasts and keratinocytes (Wehrle-Haller and
Imhof, 2003). In view of the fact that growing MTs at the
leading edge target and regulate the assembly/disassembly of
FAs (Kaverina et al., 1998; Ezratty et al., 2005; Eﬁmov et al.,
2008), we examined how the depletion of FL2 impacted the
distribution and morphology of FAs at the cell edge.
Immunoﬂuorescence measurements of vinculin, a
component of the FA complex, revealed a signiﬁcant
increase in the average area of FAs in FL2-depleted U2OS
cells compared with controls (0.87± 0.07 μm2 in controls
versus 2.54± 0.18 μm2 in FL2 siRNA-treated cells; Figure 3 c
and d). Although the FA area has long been thought to
negatively correlate with migration speed (Gardel et al.,
2011), recent reports have identiﬁed a biphasic relationship in
which cells move faster with increased FA area up to a
threshold point, beyond which cell migration slows down
(Kim and Wirtz, 2013a and b,). Strikingly, the average area of
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Figure 1. Small interfering RNA (siRNA)-mediated depletion of Fidgetin-like 2 (FL2) enhances cell migration. (a) Time-lapse images of scratch assays performed with
control or FL2 siRNA–treated U2OS cells. Scale bar = 100 μm. (b) Graphs comparing the average migration rate in control and FL2-depleted cells (n=16
monolayers). (c) Trajectories of individual control and FL2-depleted U2OS cells moving from the wound edge into the wound zone. (d) Graphs comparing the
directionality of migrating control versus FL2-depleted U2OS (n=34 cells), HaCaT, and L929 (n=57/83 cells, respectively) cells. (e) Immunoﬂuorescence micrographs
of U2OS, HaCaT, and L929 cells double-labeled for FL2 (red) and MTs (green). Scale bar = 10 μm. Inset shows a higher magniﬁcation of FL2’s co-localization with
MTs at the cortex. Scale bar = 2 μm. *Po0.05; ***Po0.0005. mean±SEM. D, distance between the start and end points; L, total path length; MT, microtubule.
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FAs in FL2-depleted cells, 2.54 μm2, is almost identical to the
FA area shown by Kim and Wirtz to correlate with the fastest
migration speed in ﬁbroblasts (Kim and Wirtz, 2013a). The FA
area was restored to control levels in FL2 siRNA–treated
U2OS cells expressing GFP–FL2 (Supplementary Figure S2B
and S2C online). HaCaTs showed a similar increase in FA
area following FL2 knockdown (Supplementary Figure S7B
online).
FL2 can be targeted to promote wound closure and regeneration
in vivo
To translate the effects of modulating FL2 expression to a
more physiologically and medically signiﬁcant model, we
investigated whether FL2 depletion can affect cell migration
during cutaneous wound healing in excisional murine
wounds (Martinez et al., 2009). Using a previously
described nanoparticle platform (Friedman et al., 2008;
Cabrales et al., 2010), we successfully encapsulated FL2
siRNA nanoparticle siRNA (NPsi) to locally and effectively
deliver intact siRNA to the wound site. After subjecting the
dorsa of BALB/c mice to 4mm full-thickness excisional
wounds, suspensions of FL2 NPsi were topically applied
directly to the wounds at either day 0 or days 0 and 2, and the
rates of wound closure were assessed relative to controls
(nontargeting control NPsi or untreated wounds). Wounds
were splinted with Tegaderm to minimize closure by
contraction (common in rodent wound models), an approach
that in our hands is comparable to glued or sutured rigid
supports but produces fewer adjacent tissue alterations. The
data plotted in Figure 4 represent wound area relative to the
initial wound area on day 0. Measurements of wounds
throughout the wound healing process demonstrated
that FL2 NPsi signiﬁcantly accelerated wound closure
in vivo with either a single application after wounding or
treatment on days 0 and 2 (Figure 4b). The addition of a
second treatment at day 2 after wounding further accelerated
the resolution of the excisional injury, demonstrating that the
cells were not refractory to RNA interference and that the
process of healing could be further beneﬁcially manipulated.
FL2 NPsi–treated excisional wounds healed faster and
remained smaller compared with control wounds throughout
the experiment. In addition, to conﬁrm in vivo FL2 knock-
down, RNA was extracted from treated wounds and measured
by quantitative PCR, which showed a signiﬁcant decrease in
FL2 expression at both 2 and 8 days after FL2 NPsi treatment
compared with controls (Figure 4c).
We further evaluated the effects of FL2 NPsi on wound
healing in a murine thermal burn wound model (Macherla
et al., 2012; Sanchez et al., 2014). In contrast to excision
wounds, full-thickness thermal burn wounds are more
traumatic secondary to heat-induced tissue coagulation, and
healing is slower because of the edema, extensive necrosis,
and hypoxia (Benson et al., 2006). Nevertheless, as with
excision wounds, burns treated topically with FL2 NPsi closed
signiﬁcantly faster compared with untreated controls
(Supplementary Figure S8A and S8B online). Control NPsi
did not enhance and even slightly attenuated burn closure
relative to controls (Supplementary Figure S9 online) and thus
was not used in this study. Quantitative PCR from wound
sections also conﬁrmed a decrease in FL2 mRNA levels after
FL2 NPsi treatment (Supplementary Figure S8C online).
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FL2 knockdown enhances the quality of wound healing
To further examine wound morphology, histopathologic
analyses were performed on formalin-ﬁxed sections of NPsi-
treated and control wounds. On day 7, hematoxylin and
eosin staining of control excisional wounds (Figure 5a)
demonstrated a thin layer of re-epithelialized epidermis with
overlying mounds of serum crust. The dermis was composed
of inﬂammatory, disorganized granulation tissue without
evidence of subcutis. This histopathology was indicative of a
disorganized wound, early in the proliferative phase of
wound healing. The residual wound areas at both time
intervals were readily distinguishable from the adjacent
intact tissues. In marked contrast, FL2 NPsi–treated exci-
sional wounds (Figure 5a) had completely re-epithelialized
the epidermis by day 7 with overlying, organized basket
weaving stratum corneum. The dermis was devoid of intense
inﬂammation and was inﬁltrated with parallel ﬁbroblasts.
A healthy appearing subcutis was also present. The
histopathology seen in FL2 NPsi–treated wounds was
indicative of a well-healed, organized scar. By day 10,
further restoration of normal tissue architecture, including
higher order structures such as hair follicles, is clearly visible
in the FL2 NPsi–treated wound but remains absent in
controls (Figure 5a).
In the control excisional day 7 wounds (Figure 5b),
Masson’s trichrome staining for collagen revealed necrotic,
degenerated collagen with minimal pale, newly deposited
collagen in the wound bed. In contrast, analysis of the NPsi-
treated wounds revealed a homogenous, well-organized,
newly formed collagen that stains light blue, and there was
minimal cell death as indicated by the lack of red staining
(Figure 5b). At day 10, collagen deposition in the control
wounds remained disorganized and rudimentary, whereas the
FL2 NPsi–treated wounds demonstrated ordered, mature
collagen deposition (Figure 5b). Similar results were identiﬁed
in burn wounds at day 10 and 13 after injury (Supplementary
Figure S10 online). The assessments at the later time intervals
were performed as re-epithelialization and organization of the
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tissue at a histopathologic level takes longer in a burn wound
as compared with an excisional injury.
DISCUSSION
The results described herein indicate that regulation of MT
function via FL2 NPsi is an innovative approach to the
treatment of various cutaneous wounds including cuts and
burns. Our complementary in vitro and in vivo studies strongly
support the hypothesis that localized depletion of FL2 induced
by the topical application of FL2 NPsi enhances wound
closure and re-epithelialization by stimulating the migration of
keratinocytes and ﬁbroblasts into the wound from the
surrounding skin. The normal regulation of FL2 during wound
regeneration and repair is an area ripe for future study as is its
potential dysregulation in chronic wounds.
FL2: an important regulator of the MTs cytoskeleton and cell
motility
A major strength of this study is the utilization of basic cell
biology to identify a clear and speciﬁc intracellular mechan-
ism of action for this potential therapeutic target. In particular,
FL2’s cortical localization, along with the increases in MT
polymer mass and bundling at the cell edge that follow its
depletion by siRNA, strongly support the hypothesis that FL2
normally suppresses cell migration by selectively shearing
MTs that contact speciﬁc sites at the cell cortex, most notably
at the leading edge. We assume that FL2 functions as a MT-
severing enzyme because of its close relationship to Fidgetin,
a known MT-severing enzyme and depolymerase (Mukherjee
et al., 2012), although this will require further experimental
validation. We recently showed that Drosophila melanogaster
cells utilize another MT-severing enzyme, Katanin, in much
the same way, indicating this to be an evolutionarily
conserved pathway (Zhang et al., 2011).
How do the alterations in MT growth and organization at
the cell edge caused by the depletion of FL2 translate into
increased cellular motility? There is now a good deal of
evidence to indicate that localized shifts in MT assembly/
disassembly at the leading edge modulate larger regulatory
pathways that control actin organization/dynamics and
FA assembly/maturation (Wehrle-Haller and Imhof, 2003;
Kaverina and Straube, 2011). Although our data are
inconclusive with regard to FL2’s impacts on actin (not
shown), we have found that FL2 strongly and signiﬁcantly
inﬂuences FAs. Indeed, depletion of FL2 appears to activate a
shift in FA size that is optimal for cell migration. Further work
will be required to determine precisely how FL2 and MTs are
linked to this shift. However, reasonable, nonexclusive
possibilities include (1) localized changes in the balance
of activities of members of the Rho family of small
GTPases, which have been found to be both sensitive to
altered MT dynamics (Krendel et al., 2002; Wittmann et al.,
2003; Wen et al., 2004) and to control FA assembly (Rooney
et al., 2010; Stehbens and Wittmann, 2012), or (2) modulation
of the motor-driven transport of FA components and
regulators along MT tracks (Miller et al., 2009; Falnikar
et al., 2011).
It is notable that FL2’s localization at the cell front is shared
by several MT stabilizers involved in actin polymerization and
FA turnover (Watanabe et al., 2005). These include APC,
ACF7, and CLASPs. Depletion of these stabilizers inhibits cell
migration in various cell types (Wen et al., 2004; Wittmann
and Waterman-Storer, 2005; Barth et al., 2008; Wu et al.,
2008, 2011; Stramer et al., 2010), implying a functional
antagonism with FL2. Research in this area may lead to
innovative approaches for precisely controlling cell motility in
a number of different therapeutic contexts.
An innovative RNA interference–based nanotherapeutic
approach to promote wound healing
Nanoscale drug delivery vehicles operate exceptionally well
as topical therapeutics because of their distinctive physical
characteristics such as high surface-to-volume ratio as a result
of their small size (Nasir 2010). These properties confer the
ability to traverse the biological barrier of the skin and allow
for rapid delivery of key biomolecules (Blecher et al., 2012).
Of particular interest within our study, nanoparticle drug
platforms are also promising for the topical delivery of siRNA,
which cannot be delivered as a therapeutic modality in its
naked form because it is susceptible to degradation by
endogenous enzymes, and because its large size and negative
charge hamper its ability to cross lipophilic cellular
membrane (Castanotto and Rossi, 2009). Moreover, we
found no evidence of toxicity of the nanoparticles
(Friedman et al., 2008; Han et al., 2009), and encapsulation
of the siRNA likely minimizes interaction with innate immune
receptors (Robbins et al., 2009). Capitalizing on the attributes
of nanomaterials, our ﬁndings reveal that FL2 NPsi has the
potential to serve as a topical modality for wound healing by
accelerating wound closure, as well as enhancing the
maturation rate of the wound structure.
MATERIALS AND METHODS
Antibody production
Monoclonal antibodies against human FIGNL2 (NM_001013690)
were generated in mice (Abmart, Shanghai, China) using the
following peptides: antiFL2-1 (SSTTPSPAHK), antiFL2-2 (TPE-
HAQPLNQ), and antiFL2-3 (SGETPKGVDP).
Commercial antibodies
We used the following antibodies for immunoﬂuorescence: mouse
anti-tubulin (Fisher Scientiﬁc, Waltham, MA, MS581P1), rabbit anti-
tubulin (Abcam, Cambridge, UK, Ab18251), mouse anti-acetylated
tubulin (Sigma-Aldrich, St Louis, MO, T6793), mouse anti-EB1
(BD Transduction Laboratories, San Jose, CA, 610534), mouse
anti-vinculin (Abcam, ab18058), Cy2-conjugated Anti-mouse
IgG, Cy2-conjugated Anti-Rabbit IgG, Rhodamine Anti-mouse
IgG, and Rhodamine Anti-Rabbit IgG (Jackson Laboratories,
Bar Harbor, ME).
Plasmid construction and expression
The N-terminal GFP-tagged construct of FL2 was constructed from
pANT7_cGST (DNASU, Arizona State University, Tempe, AZ, clone:
HsCD00403041) and subcloned into pEGFP–C1. The construct was
expressed in U2OS using Lipofectamine 2000 (Life Technologies,
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Norwalk, CT, 11668027). Twenty-four hours after plasmid transfec-
tion, U2OS cells were ﬁxed and labeled with anti-GFP antibody
(Abcam, ab290).
Cell culture and siRNA treatment
U2OS are from ATCC (ATCC, Manassas, VA), U2OS-EB1 (a gift from
Dr Pavel Draber (Vinopal et al., 2012)), and HaCaT (a gift from Dr
Paul Higgins) cells were cultured in DMEM (Life Technologies,
11965092) supplemented with 10% fetal bovine serum and 1%
Glutamax at 37 °C in the presence of 5% CO2. L929s (a gift from
Dr Bin Zhou) were cultured in EMEM (ATCC, 30–3000) and 10%
fetal bovine serum, under the same conditions.
For in vitro FL2 knockdown studies, cells were transfected using
2.5 μl Lipofectamine RNAiMAX (Life Technologies, 13778075) or 7.5
Lipofectamine 3000 with 40 or 75 pmol, respectively, of either FL2
siRNA (GE Dharmacon, Lafayette, CO, ON-TARGETplus set of four),
mouse FL2 (Sigma-Aldrich, SASI_Mm02_00354635), or a negative
control siRNA (Sigma-Aldrich, SIC001).
For FL2 rescue experiments, 24 hours after siRNA treatment, U2OS
cells were transfected with 1.5 μg of either pEGFP–C1 or pEGFP–FL2
using 4 μl of Lipofectamine 2000. The medium was replaced 5 hours
later, and cells were processed the next day depending on the
experiments (see below).
Unless otherwise noted, experiments in U2OS cells were repeated
three times and experiments in HaCaT and L929 cells were repeated
twice independently.
In vitro scratch and single cell migration assays
For scratch assays, cell monolayers were scratched 48 hours
after siRNA treatment (24 hours after plasmid expression for
FL2 rescue experiments) with a 200 μl pipette tip. For single
cell migration assays, HaCaTs were plated at low cell density to
allow for single cell movement. Cell migration was imaged by
time-lapse microscopy at 20–30 minutes intervals overnight in
an environmental chamber using an Inverted Olympus (Tokyo,
Japan) IX71 microscope with a 10× (0.3 numerical aperture)
objective and a Photometrics (Tucson, AZ) CoolSnap HQ CCD
camera. Movies were analyzed using ImageJ (National Institute of
Health, Bethesda, MD), and individual cells were tracked with its
Manual Tracking plugin. The migration rate was calculated either by
dividing the change in the area by length of the ﬁxed image edge and
ﬁnally by the number of hours or by tracking individual cells.
Analysis of the cell tracks was performed using DiPer (Gorelik and
Gautreau, 2014).
Proliferation assay
Twenty-four hours before siRNA treatment, equal amounts of cells
were plated in triplicate in either 6- or 24-well plates. Cells were
detached and counted 24, 48, and 72 hours after siRNA treatment
using a hemocytometer.
Quantitative PCR
Unless otherwise noted, supplies for RNA quantiﬁcation were
purchased from Life Technologies. For tissue culture samples, mRNA
was extracted using the Purelink RNA mini kit (12183018A).
Complementary DNA was synthesized the same day using the
SuperScript III First-strand synthesis system (18080051). Quantitative
PCR was performed using Life Technologies Universal Master Mix II
(4440040) with Life Technologies hFIGNL2 primers (4448892).
hGAPDH was used as a control (4331182).
Alternatively, for mouse skin wound samples, the skin of control and
FL2NPsi-treated wounds was excised at day 2 and 8 after wounding.
Trizol (15596-026) was used to pulverize the tissue and a standard
RNA extraction protocol was followed. Complementary DNA synth-
esis was performed as described above. Quantitative PCR was
performed using PowerSybr green Master Mix with mFIGNL2 primers
and mGAPDH (IDT (Integrated DNA Technologies, Coralville, IA)) or
mActin (IDT) was used as loading controls. The complementary DNA
was ampliﬁed using the 7300 Real-Time PCR system (Applied
Biosystems, Waltham, MA). Resulting data were quantiﬁed using the
comparative 2−ΔΔCt method. The average of control skin wounds was
normalized to 1 and used for relative quantiﬁcation.
Western blotting
Western blot analysis was performed using cells frozen 72 hours after
siRNA treatment as described in (O’Rourke et al., 2014).
Immunoﬂuorescence microscopy
Cells were grown on coverslips for 48 hours after siRNA treatment
(18 hours after plasmid expression for FL2 rescue experiments) and
then ﬁxed for 10 minutes with a ﬁxative solution (4% paraformalde-
hyde, 0.1% Triton X, and 0.15% glutaraldehyde in BRB80), and a
standard immunolabeling protocol was followed.
Cells were imaged using a 4-D spinning-disk confocal micro-
scope (PerkinElmer, Waltham, MA) with either a 40× (1.3 numerical
aperture), a 60× (1.4 numerical aperture), or a 100× (1.4 numerical
aperture) objective and a digital camera (Orca ER; Hamamatsu).
Z planes= 0.5 μm.
Nanoparticle encapsulated siRNA preparation
Five hundred microlitres of Tetramethyl orthosilicate (TMOS) was
hydrolyzed in the presence of 100 μl of 1 mM HCl by sonication on
ice for about 15 minutes, until a single phase formed. The hydrolyzed
TMOS (100 μl) was added to 900 μl of 20 μM of siRNA (mouse FL2
(Sigma-Aldrich, SASI_Mm02_00354635) or the negative control)
solution containing 10mM phosphate, pH 7.4. A gel was formed
within 10 minutes. The gel was frozen at − 80 °C for 15 minutes and
lyophilized.
In vivo experiments
Animal experiments were performed according to the guidelines
published by the Institute of Laboratory Animal Resources of
National Research Council and animal care for this study was
approved by the Institutional Animal Care and Use Committee of the
Albert Einstein College of Medicine. Two murine wound models
were utilized: a full-thickness wound model and a thermal burn
wound model. Prior to procedures, mice were anesthetized with a
ketamine–xylazine cocktail. The dorsa of Balb/c mice (6–8 weeks;
National Cancer Institute, Frederick, MD) were depilated and
wounded with either a 4mm punch biopsy (Integra Miltex, York,
PA) or a thermal burn. Uniform, reproducible burn wounds were
produced with a heated brass knob (1.27 cm diameter; 45 seconds
until reaching 180–200 °C measured by calorimeter). Wounds were
splinted with Tegaderm in which circular openings were created to
enable the dressings to be seated immediately adjacent to the
wounds. Nuclease-free water was used to suspend the NPsi. Using a
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micropipette, nuclease-free water alone, non-targeting NPsi or FL2
NPsi was topically applied to the wound beds in single doses (100
pmol of siRNA) immediately after wounding on day 0 or at both days
0 and 2. Control groups were either treated with nontargeting NPsi
on a schedule correlating with the FL2 NPsi or were not treated.
Wounds were serially photographed and measured independently by
two readers using calipers to track the progression of wound closure.
Mice were randomly selected for euthanization on designated days,
and tissue from the wounds was excised for both PCR and
histopathologic analysis. For histopathology, tissue was embedded
in parafﬁn, sectioned in 10 μm sections, and stained with hematox-
ylin and eosin or Masson’s trichrome.
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